Our Neoantigen Selection Platform, known as NSP, is how the company decides, for each patient, which of a tumor's mutations are worth turning into medicine.
Cancer remains one of the leading causes of death. Outside of surgery or immunotherapy, targeted therapy usually isn't curative. Several vaccine trials, across peptide, DNA and mRNA platforms, have already produced real, measurable results. The pattern across the field is that immune responses are common; making strong, durable results consistent from patient to patient is the harder problem. Rescue Bio exists to close that gap. See the full evidence base.
The pipeline runs from sequencing through mutation calling, patient HLA typing, RNA-confirmed candidate generation, multi-dimensional scoring, and a capped, logged peptide pool, ending in human review before manufacturing.
Candidates are usually scored almost entirely on how strongly a peptide binds and how much of it the tumor expresses. It is a real signal, but an incomplete one.
NSP weights candidates by whether the mutation is present in the tumor's stem-like, treatment-resistant cell population, not just the bulk tumor. It is a bet on preventing recurrence, not only shrinking the tumor today.
The company's initial focus is glioblastoma and pancreatic cancer, both essentially incurable once standard therapy is exhausted, with plans to expand into breast, renal and ovarian cancers.